New Delhi: Dr Reddy’s Laboratories (DRL) said it has launched in the US market generic Tetrabenazine tablets used for the treatment of involuntary movements associated with Huntington’s disease.
The company’s Tetrabenazine tablets have been approved by the United States Food and Drug Administration (USFDA), Dr Reddy’s Laboratories said in a filing to the BSE.
Tetrabenazine is a generic version of Valeant Pharmaceuticals Luxembourg S A R L’s Xenazine tablets, it added.
According to IMS Health data, Xenazine brand and generic had US sales of approximately USD 322 million MAT for the most recent twelve months ending in November 2017, Dr Reddy’s Laboratories said.
The company’s Tetrabenazine tablets are available in strengths of 12.5 mg and 25 mg, it added.